Description

BSE/ICCL notice detailing the settlement schedule for the Offer to Buy acquisition window under the buyback program for Windlas Biotech Limited.

Summary

BSE, through its clearing corporation ICCL, has issued Notice No. 20260429-2 dated 29 April 2026 outlining the settlement schedule for the Offer to Buy – Acquisition Window (Buyback) for Windlas Biotech Limited. This notice is directed at trading and settlement participants involved in the buyback acquisition window for this scrip.

Key Points

  • Notice issued by ICCL (Indian Clearing Corporation Limited) under the Settlement/RMS category.
  • Pertains to the Offer to Buy – Acquisition Window mechanism used for buyback of shares of Windlas Biotech Limited.
  • Segment classified as General; no attachments included with the notice.
  • Settlement schedule details govern how trades executed during the buyback acquisition window will be settled.

Regulatory Changes

No new regulatory changes introduced. This notice operationalizes existing SEBI buyback regulations by specifying the settlement timeline applicable to the Windlas Biotech buyback acquisition window.

Compliance Requirements

  • Trading members and custodians participating in the Windlas Biotech buyback acquisition window must adhere to the settlement schedule as specified by ICCL.
  • Participants should ensure timely delivery of shares and funds in accordance with the prescribed settlement obligations.

Important Dates

  • Notice Date: 29 April 2026
  • Settlement dates: As per the schedule detailed in the official notice (refer to the PDF for specific settlement day timelines).

Impact Assessment

This notice has a contained, company-specific impact limited to shareholders and market participants trading in Windlas Biotech Limited shares during the buyback acquisition window. It ensures orderly settlement of buyback trades and carries no broader systemic or market-wide implications.

Impact Justification

Company-specific buyback settlement notice relevant to shareholders and traders of Windlas Biotech; operational/settlement guidance with limited broader market impact.